Starling Oncology, Inc. (STLN) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Starling Oncology, Inc. (STLN) stock forecast summary
Our AI ranks Starling Oncology, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Its market capitalization is not available, so no size classification is given.
A per-ticker accuracy statistic for STLN is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, STLN included.
Follow STLN freeSTLN price chart and AI forecast
How STLN ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Starling Oncology, Inc. (STLN) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Offices & Clinics of Doctors of Medicine peers listed below that report each metric.
Valuation & Market
| Metric | STLN | Rank |
|---|---|---|
| EPS | $-0.47 | – |
Profitability & Margins
| Metric | STLN | Rank |
|---|---|---|
| ROA | -20.4% | 6/8 |
| ROIC | -31.3% | 7/8 |
| Operating Margin | -4.4% | 3/8 |
| Net Margin | -6.2% | 5/8 |
| EBT Margin | -6.2% | 2/8 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | STLN | Rank |
|---|---|---|
| Current Ratio | 1.36x | 2/8 |
| Quick Ratio | 1.15x | 2/6 |
| Interest Coverage | -5.3x | 4/8 |
| Working Capital | $34M | 2/8 |
Cash Flow
| Metric | STLN | Rank |
|---|---|---|
| Operating Cash Flow | $330K | 5/8 |
| Free Cash Flow | -$3M | 5/6 |
| Capital Spending | -$4M | 4/6 |
| FCF/Sales | -0.6% | 5/6 |
| CapEx/Sales | 0.6% | 3/6 |
Operational Efficiency
| Metric | STLN | Rank |
|---|---|---|
| Asset Turnover | 3.29x | 1/7 |
| Receivables Turnover | 8.8x | – |
| Fixed Assets Turnover | 55.5x | 3/6 |
| Days Sales Outstanding | 41 days | – |
Income Statement
| Metric | STLN | Rank |
|---|---|---|
| Total Revenue | $587M | 3/7 |
| Operating Income | -$26M | 6/8 |
| Net Income | -$36M | 6/8 |
| SG&A Expense | $111M | 3/7 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $129M | 72.4% of assets |
| Cash & Short-term Investments | $41M | 23.1% of assets |
| Accounts Receivable | $66M | 37.2% of assets |
| Inventory | $20M | 11.2% of assets |
| Total Liabilities | $203M | 114.0% of assets |
| Short-term Debt | $35M | 19.4% of assets |
STLN quarterly financials and insider trading
Starling Oncology, Inc. (STLN) industry peers
Companies classified under the same SEC industry code as Starling Oncology, Inc. (Services-Offices & Clinics of Doctors of Medicine): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| STLN Starling Oncology, Inc. | ▲ | N/A |
| TDOC Teladoc Health, Inc. | ▶ | $1.09B |
| SBC Sbc Medical Group Holdings Inc | ▼ | $547M |
| LFMD Lifemd, Inc. | ▲ | $119M |
| AIRS Airsculpt Technologies, Inc. | ▲ | $117M |
| HLYK Healthlynked Corp | ▲ | $6M |
| CDIX Cardiff Lexington Corp | ▼ | N/A |
| HIMS Hims & Hers Health, Inc. | ▶ | N/A |
Where STLN sits on the market map
Starling Oncology, Inc. (STLN) stock news
Loading...
Starling Oncology, Inc. (STLN) stock forecast FAQ
What is the Starling Oncology, Inc. (STLN) stock forecast?
Our AI ranks Starling Oncology, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Starling Oncology, Inc. stock predictions?
A per-ticker accuracy statistic for STLN is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Starling Oncology, Inc. forecasts updated?
Starling Oncology, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Starling Oncology, Inc.'s industry peers?
8 issuers in our coverage, STLN included, share the SEC industry code Services-Offices & Clinics of Doctors of Medicine. The largest are: Teladoc Health, Inc. (TDOC), Sbc Medical Group Holdings Inc (SBC), Lifemd, Inc. (LFMD), Airsculpt Technologies, Inc. (AIRS), Healthlynked Corp (HLYK), Cardiff Lexington Corp (CDIX).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.